Melbourne, Australia; 27 July 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today released its Quarterly Activity
Report for the three-month period ended 30 June 2022.
Key highlights: • US Food and Drug Administration (FDA) clears Cynata’s Investigational New Drug (IND) application for a Phase 2 trial in acute graft-versus-host disease (aGvHD)
o trial expected to commence in the US by the end of 2022
o confirms quality of the product data package: critical validation step for the Company’s ongoing commercial partnering activities
• Actively recruiting and treating patients in three clinical trials:
o the Phase 3 SCUlpTOR osteoarthritis clinical trial, o the MEND respiratory distress clinical trial and, o the Diabetic Foot Ulcers (DFU) clinical trial
• Added a new site for the MEND clinical trial, expanding the potential pool of patients and accelerating trial progress
• Reported compelling data from a preclinical study in idiopathic pulmonary fibrosis(IPF), which supports the potency and molecular mechanisms of action of Cynata’s proprietary Cymerus™ MSC technology
• Strong financial position with A$23.8m in cash as at 30 June 2022
CYP Price at posting:
40.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)